Atara Biotherapeutics, Inc. ATRA · Stock Open Atara Biotherapeutics, Inc. in new tab
Atara Biotherapeutics, Inc. Analysis (ATRA)
Is Atara Biotherapeutics, Inc. a good investment? Atara Biotherapeutics, Inc. (ATRA) is currently trading at 8.46 USD. Market analysts have a consensus price target of 13.67 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 1.91. This relatively low multiple may signal that Atara Biotherapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Atara Biotherapeutics, Inc. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is 1.55.
Investor FAQ
Does Atara Biotherapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Atara Biotherapeutics, Inc.?
Atara Biotherapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.54.
Company Profile
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Split Date | Split Ratio to 1 |
|---|---|
| June 20, 2024 | 1:25 |
Community Discussion